ArticleFrontiers in microbiology2020
Prevalence and Characterization of Carbapenem-Hydrolyzing Class D β-Lactamase-Producing
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- A systematic review and meta-analysis of carbapenem-resistant Enterobacteriaceae in West Africa.BMC medical genomics · 2024Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Article
- Phenotype-Genotype Discordance in Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2026Review
- Whole genome analysis of carbapenem resistantNew microbes and new infections · 2026Article
- Genomic characterisation of extensively drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Ghana.PloS one · 2026Article
- Relationship between antibiotic resistance and biofilm-forming capacity with RND efflux pumps expression in clinical Acinetobacter baumannii isolates.Archives of microbiology · 2025Article
- Secondary bacterial infections of Carbapenem-Resistant Acinetobacter baumannii in patients with COVID-19 admitted to Chinese ICUs.BMC microbiology · 2025Article
- Environmental Risk Factors Contributing to the Spread of Antibiotic Resistance in West Africa.Microorganisms · 2025Review
- Article
- Screening for Resistant Bacteria, Antimicrobial Resistance Genes, Sexually Transmitted Infections andPathogens (Basel, Switzerland) · 2023Article
- Carbapenem-ResistantCase reports in infectious diseases · 2023Article
- Emergence of a ST248Infection and drug resistance · 2023Article
- Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2022Article
- Epidemiology of Plasmids inAntibiotics (Basel, Switzerland) · 2022Article
- Environmental surveillance of ESBL and carbapenemase-producing gram-negative bacteria in a Ghanaian Tertiary Hospital.Antimicrobial resistance and infection control · 2022Article
- Rectal Colonization and Nosocomial Transmission of Carbapenem-ResistantFrontiers in medicine · 2022Article
- Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?Infection and drug resistance · 2022Review
- High Prevalence of Carbapenemase-ProducingMicroorganisms · 2021Article
- Emergence of ST63 Pandrug-ResistantFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance, especially carbapenem resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.